IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response

Cancer Research

Volumn 72, Issue 3, 2012, Pages 592-603

  Núñez, Nicolás Gonzalo ^a   Andreani, Virginia ^a   Crespo, María Inés ^a   Nocera, David Andrés ^a   Breser, María Laura ^a   Morón, Gabriel ^a   Dejager, Lien ^b   Libert, Claude ^b   Rivero, Virginia ^a   Maccioni, Mariana ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON; INTERFERON ANTIBODY; INTERFERON RECEPTOR; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME REGULATION; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; ANTIGENS, CD11C; BONE MARROW CELLS; CELL LINE, TUMOR; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; INTERFERON-BETA; LIPOPOLYSACCHARIDES; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4;

EID: 84856527731     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-0534     Document Type: Article

References (48)

1. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-20.
2. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-84.
3. Dubensky TW, Reed SG. Adjuvants for cancer vaccines. Semin Immunol 2010;22:155-61.
4. Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009;183:6186-97.
5. Chicoine MR, Zahner M, Won EK, Kalra RR, Kitamura T, Perry A, et al. The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery 2007;60:372-80.
6. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, et al. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007;563:1-17. (Pubitemid 46628799)
7. de Bono JS, Dalgleish AG, Carmichael J, Diffley J, Lofts FJ, Fyffe D, et al. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacteria lipopolysaccharide. Clin Cancer Res 2000;6:397-405. (Pubitemid 30111456)
8. Okamoto M, Oshikawa T, Tano T, Sasai A, Kan S, Moriya Y, et al. Mechanism of anticancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother 2006;29:78-86.
9. Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res 1991;51:2524-30.
10. Lundin JI, Checkoway H. Endotoxin and cancer. Environ Health Perspect 2009;117:1344-50.
11. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009;9:57-63.
12. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll like receptor 4-dependent contribution of the immune system to anticancer chemotherapy. Nature Med 2007;13:1050-9. (Pubitemid 47517504)
13. Earl TM, Nicoud IB, Pierce JM, Wright JP, Majoras NE, Rubin JE, et al. Silencing of TLR4 decreases liver tumor burden in a murine model of colorectal metastasis and hepatic steatosis. Ann Surg Oncol 2009;16:1043-50.
14. Mittal D, Saccheri F, Vénéreau E, Pusterla T, Bianchi ME, Rescigno M. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J 2010;29:2242-5.
15. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res 2005;65:5009-13.
16. Doan HQ, Bowen KA, Jackson LA, Evers BM. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res 2009;29:2473-8.
17. Szczepanski MJ, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A, et al. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res 2009;69:3105-13.
18. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006;131:862-77. (Pubitemid 44316821)
19. Szajnik M, Szczepanski MJ, Czystowska M, Elishaev E, Mandapathil M, Nowak-Markwitz E, et al. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009;28:4353-63.
20. Yang HZ, Cui B, Liu HZ, Mi S, Yan J, Yan HM, et al. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One 2009;4:6520-27.
21. Rhee SH, Im E, Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008;135:518-28.
22. Yusuf N, Nasti TH, Long JA, Naseemuddin M, Lucas AP, Xu H, et al. Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res 2008;68:615-22. (Pubitemid 351380091)
23. Nair P, O'Donnell CM, Janasek K, Sajduk MK, Smith EA, Golden JM, et al. Lipopolysaccharide-treated mammary carcinomas secrete proinflammatory chemokines and exhibit reduced growth rates in vivo, but not in vitro. Immunol Invest 2009;38:730-48.
24. Andreani V, Gatti G, Simonella L, Rivero V, Maccioni M. Activation of Toll-like receptor 4 on tumor cells in vitro inhibits subsequent tumor growth in vivo. Cancer Res 2007;67:10519-27. (Pubitemid 350070828)
25. Gatti G, Rivero V, Motrich RD, Maccioni M. Prostate epithelial cells can act as early sensors of infection by up-regulating TLR4 expression and proinflammatory mediators upon LPS stimulation. J Leukoc Biol 2006;79:989-98. (Pubitemid 44835586)
26. Magram J, Connaughton SE, Warrier RR, Carvajal DM, Wu CY, Ferrante J, et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity 1996;4:471-81. (Pubitemid 26354656)
27. Inaba K, Swiggard WJ, Steinman RM, Romani N, Schuler G, Brinster C. Isolation of dendritic cells. Curr Protoc Immunol 2009;Chapter 3: Unit 3.7.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 2001;25:402-8. (Pubitemid 34164012)
29. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96. (Pubitemid 46697910)
30. Kusmartsev S, Gabrilovich DI. Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer. Cancer Metastasis Rev 2006;25:323-31. (Pubitemid 44922353)
31. Idoyaga J, Moreno J, Bonifaz L. Tumor cells prevent mouse dendritic cell maturation induced by TLR ligands. Cancer Immunol Imunother 2007;56:1237-50. (Pubitemid 46947944)
32. Gautier G, Humbert M, Deauvieau F, Scuiller M, Hiscott J, Bates EE, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005;201:1435-46. (Pubitemid 40664087)
33. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, et al. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 2007;178:2883-92. (Pubitemid 46333166)
34. Coccia EM. IFN regulation and functions in myeloid dendritic cells. Cytokine Growth Factor Rev 2008;19:21-32. (Pubitemid 351200061)
35. Reinhardt RL, Bullard DC, Weaver CT, Jenkins MK. Preferential accumulation of antigen-specific effector CD4 T cells at an antigen injection site involves CD62E-dependent migration but not local proliferation. J Exp Med 2003;197:751-62. (Pubitemid 36350870)
36. Gerner MY, Mescher MF. Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol 2009;182:2726-37.
37. Preynat-Seauve O, Schuler P, Contassot E, Beermann F, Huard B, French LE. Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol 2006;176:61-7. (Pubitemid 43023249)
38. Alshamsan A, Hamdy S, Das S, Lavasanifar A, Samuel J, El-Kadi AO. Validation of bone marrow derived dendritic cells as an appropriate model to study tumor-mediated suppression of DC maturation through STAT3 hyperactivation. J Pharm Pharm Sci 2010;13:21-6.
39. Kalaaji AN, Lu J, Markovic SN, Celis E, Pittelkow MR. Combination cytokine therapy inhibits tumor growth by generation of tumor-specific T-cell responses in a murine melanoma model. Cytokine 2010;49:287-93.
40. Gerosa F, Baldani-Guerra B, Lyakh LA, Batoni G, Esin S, Winkler-Pickett RT, et al. Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells. J Exp Med 2008;205:1447-61. (Pubitemid 351831499)
41. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19:641-4. (Pubitemid 37490789)
42. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48. (Pubitemid 44631652)
43. Trinchieri G. Type I interferon: friend or foe? J Exp Med 2010;207:2053-63.
44. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001;6:34-55 (Pubitemid 32155814)
45. Jablonska J, Leschner S, Westphal K, Lienenklaus S, Weiss S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010;120:1151-64.
46. U'Ren L, Guth A, Kamstock D, Dow S. Type I interferons inhibit the generation of tumor-associated macrophages. Cancer Immunol Immunother 2010;59:587-98.
47. Qin XQ, Tao N, Dergay A, Moy P, Fawell S, Davis A, et al. Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 1998;95:14411-6. (Pubitemid 28549381)
48. Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, et al. Type III IFN interleukin-28mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res 2010;70:4539-49.